NASDAQ : ZVRA
Zevra Therapeutics, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 10.36 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 615.22M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 610.47M |
| Enterprise Value | 390.39M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 3, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 59.38M |
| Shares Outstanding | 59.38M |
| Shares Change (YoY) | +13.46% |
| Shares Change (QoQ) | +1.84% |
| Owned by Insiders (%) | 1.22% |
| Owned by Institutions (%) | 71.82% |
| Float | 53.87M |
Ratios
| Measure | Value |
|---|
| PE Ratio | 10.71 |
| Forward PE | 12.05 |
| PS Ratio | 4.49 |
| Forward PS | 3.70 |
| PB Ratio | 2.80 |
| P/TBV Ratio | 2.95 |
| P/FCF Ratio | 18.71 |
| P/OCF Ratio | 18.28 |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | 6.82 |
| EV / Sales | 2.87 |
| EV / EBITDA | 9.63 |
| EV / EBIT | 9.99 |
| EV / FCF | 11.97 |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 5.17 |
| Quick Ratio | 5.02 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | 0.04 |
| Debt / FCF | 0.05 |
| Interest Coverage | 6.84 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | 34.80% |
| Return on Assets (ROA) | 8.74% |
| Return on Invested Capital (ROIC) | -14.18% |
| Return on Capital Employed (ROCE) | 15.38% |
| Weighted Average Cost of Capital (WACC) | 10.41% |
| Revenue Per Employee | $2.23M |
| Profits Per Employee | $938,475 |
| Employee Count | 61 |
| Asset Turnover | 0.49 |
| Inventory Turnover | 3.47 |
Taxes
| Measure | Value |
|---|
| Income Tax | 11.03M |
| Effective Tax Rate | 15.91% |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 0.98 |
| 52-Week Price Change | +1.58% |
| 50-Day Moving Average | 11.18 |
| 200-Day Moving Average | 10.75 |
| Relative Strength Index (RSI) | 45.70 |
| Average Volume (20 Days) | 763,080 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 6.23M |
| Short Previous Month | 7.15M |
| Short % of Shares Out | 10.48% |
| Short % of Float | 11.56% |
| Short Ratio (days to cover) | 6.56 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 136.07M |
| Gross Profit | 129.89M |
| Operating Income | 39.07M |
| Pretax Income | 69.29M |
| Net Income | 57.25M |
| EBITDA | 40.55M |
| EBIT | 39.07M |
| Earnings Per Share (EPS) | $0.96 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 221.57M |
| Total Debt | 1.50M |
| Net Cash | 220.07M |
| Net Cash Per Share | $3.71 |
| Equity (Book Value) | 217.65M |
| Book Value Per Share | 3.67 |
| Working Capital | 202.67M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | 33.40M |
| Capital Expenditures | -775,000 |
| Depreciation & Amortization | 1.49M |
| Net Borrowing | -60.09M |
| Free Cash Flow | 32.62M |
| FCF Per Share | $0.55 |
Margins
| Measure | Value |
|---|
| Gross Margin | 95.46% |
| Operating Margin | 28.71% |
| Pretax Margin | 50.92% |
| Profit Margin | 42.82% |
| EBITDA Margin | 29.80% |
| EBIT Margin | 28.71% |
| FCF Margin | 23.98% |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -13.46% |
| Shareholder Yield | -13.46% |
| Earnings Yield | 9.34% |
| FCF Yield | 5.34% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $25.25 |
| Price Target Difference | 145.62% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 9 |
| Revenue Growth Forecast (3Y) | 28.37% |
| EPS Growth Forecast (3Y) | 10.94% |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Dec 28, 2020 |
| Split Type | Reverse |
| Split Ratio | 1:16 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | 3.92 |
| Piotroski F-Score | 5 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside | |